Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

5.3K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
CRISPR01:59

CRISPR

46.0K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
46.0K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

3.0K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
3.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From local to systemic: spinal aging in the multi-organ aging network.

Ageing research reviews·2026
Same author

Youthful-state extracellular vesicles for targeted therapy of intervertebral disc degeneration: resolving inflammation and pyroptosis through NF-<i>Îș</i>B suppression and NLRP1 inactivation.

Biomedical materials (Bristol, England)·2026
Same author

Dysregulated methylation‒ubiquitination crosstalk accelerates intervertebral disc degeneration via MED12 destabilization and cGAS/STING activation.

The Journal of clinical investigation·2026
Same author

Piezo1-activated mesenchymal stem cells-derived extracellular matrix hydrogel promotes the repair of osteoporotic bone defects through osteogenic and angiogenic coupling.

Regenerative biomaterials·2026
Same author

Biomechanical differences between occipital plate and modified C1 lateral mass screw in the treatment of complex craniocervical malformations: a finite element analysis.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2026
Same author

Sagittal spinal alignment in adolescent idiopathic scoliosis: a narrative review of pre- and post-treatment characteristics.

EFORT open reviews·2026

Related Experiment Video

Updated: Apr 21, 2026

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

12.2K

Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.

Yong Feng1, Slim Sassi, Jacson K Shen

  • 1Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Jackson 1115, 02114, Boston, Massachusetts; Department of Orthopaedic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jie Fang Avenue, 430022, Wuhan, China.

Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society
|October 29, 2014
PubMed
Summary

Targeting the CDK11 gene using CRISPR-Cas9 effectively inhibits osteosarcoma cell growth and survival. This novel genome editing approach shows promise as a potential therapeutic strategy for osteosarcoma treatment.

Keywords:
CDK11CRISPR-Cas9osteosarcoma

More Related Videos

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

819
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

10.2K

Related Experiment Videos

Last Updated: Apr 21, 2026

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells
10:21

Using CRISPR/Cas9 Gene Editing to Investigate the Oncogenic Activity of Mutant Calreticulin in Cytokine Dependent Hematopoietic Cells

Published on: January 5, 2018

12.2K
Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

819
Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
07:56

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

10.2K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma is a primary bone cancer with poor prognosis for metastatic or recurrent cases.
  • Current chemotherapy offers limited efficacy for advanced osteosarcoma.
  • CDK11 has been identified as crucial for osteosarcoma cell proliferation and survival.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting the CDK11 gene in osteosarcoma.
  • To evaluate the efficacy of the CRISPR-Cas9 system in gene editing for osteosarcoma.
  • To determine the impact of CDK11 gene knockout on osteosarcoma cell behavior.

Main Methods:

  • Utilized the CRISPR-Cas9 genome editing system to target the endogenous CDK11 gene in osteosarcoma cell lines (KHOS and U-2OS).
  • Assessed the efficiency of CDK11 gene silencing via CRISPR-Cas9.
  • Evaluated the effects of CDK11 inhibition on cell proliferation, viability, death, migration, and invasion.

Main Results:

  • CRISPR-Cas9 efficiently silenced CDK11 expression in osteosarcoma cells.
  • CDK11 inhibition led to reduced cell proliferation and viability.
  • CDK11 knockout induced cell death and significantly decreased migration and invasion capabilities.

Conclusions:

  • The CRISPR-Cas9 system is an effective tool for modifying endogenous CDK11 gene expression.
  • Targeting CDK11 via CRISPR-Cas9 mediated knockout presents a promising therapeutic strategy for osteosarcoma.
  • Further research into CDK11 as a therapeutic target could improve osteosarcoma patient outcomes.